Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis.

Autor:	Marx JL; Doheny Eye Institute, Department of Ophthalmology, University of Southern California School of Medicine, Los Angeles, USA., Kapusta MA, Patel SS, LaBree LD, Walonker F, Rao NA, Chong LP
Jazyk:	angličtina
Zdroj:	Archives of ophthalmology (Chicago, Ill. : 1960) [Arch Ophthalmol] 1996 Jul; Vol. 114 (7), pp. 815-20.
DOI:	10.1001/archopht.1996.01100140029003
Abstrakt:	Objective: To evaluate the efficacy of the ganciclovir implant in the treatment of recurrent cytomegalovirus (CMV) retinitis. Methods: Patients with acquired immunodeficiency syndrome and recurrent CMV retinitis were evaluated for entry into the study. A ganciclovir implant was inserted in 91 eyes of 70 patients between October 1992 and October 1995. The efficacy of the implant and visual results were retrospectively reviewed. Results: Fifty-three (76%) of 70 eyes had inactive CMV retinitis 1 month postoperatively (positive initial response). Twenty-one eyes of 19 patients had less than 1 month of follow-up. Nineteen (36%) of 53 eyes developed recurrent CMV retinitis. The median time to recurrence for those patients with a positive initial response was 7 months. Forty-eight (84%) of 57 patients with follow-up longer than 1 month after implant insertion in the first eye received systemic anti-CMV medication during the study. The cumulative risk for developing a retinal detachment was 23% at 6 months following implant insertion. Other complications included vitreous hemorrhage, hyphema, and suprachoroidal implantation of the device. Conclusion: The ganciclovir implant is effective as an adjunct to continued systemic therapy in those patients with recurrent CMV retinitis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu